Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of pati...
Publications
2 shownClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that the...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 5,299
- Institution
- The University of Texas MD Anderson Cancer Center
External Links
Identifiers
- ORCID
- 0000-0003-0694-0530
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.